- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
19 result(s) found for: Brustkrebs.
Displaying page 1 of 1.
EudraCT Number: 2018-002998-21 | Sponsor Protocol Number: CLEE011O12301C | Start Date*: 2019-02-25 | ||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
Full Title: A phase III, multicenter, randomized, open-label trial toevaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-... | ||||||||||||||||||
Medical condition: hormone receptor-positive, HER2-negative, early breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) IE (Ongoing) HU (Ongoing) AT (Ongoing) BE (Ongoing) DE (Restarted) FR (Ongoing) PL (Ongoing) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002080-93 | Sponsor Protocol Number: EGF103659 | Start Date*: 2006-10-06 |
Sponsor Name:Glaxo SmithKline Research and Development Limited | ||
Full Title: An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer | ||
Medical condition: ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) NL (Completed) BE (Completed) PT (Completed) CZ (Completed) SK (Completed) IS (Completed) DE (Completed) AT (Completed) EE (Completed) GR (Completed) DK (Completed) FI (Completed) SE (Completed) IT (Prematurely Ended) MT (Completed) SI (Completed) GB (Completed) BG (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001189-87 | Sponsor Protocol Number: SAKK96/12 | Start Date*: 2017-07-18 | ||||||||||||||||
Sponsor Name:Swiss Group for Clinical Cancer Research | ||||||||||||||||||
Full Title: Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks - A Non-Inferiority Phase III trial | ||||||||||||||||||
Medical condition: Bone metastases from castration resistant prostate cancer or from breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004100-35 | Sponsor Protocol Number: GBG102-SASCIA | Start Date*: 2020-10-09 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GBG Forschungs GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treat... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) IE (Ongoing) ES (Ongoing) AT (Ongoing) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002505-35 | Sponsor Protocol Number: ABCSG_50 | Start Date*: 2018-06-25 | |||||||||||||||||||||
Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group) | |||||||||||||||||||||||
Full Title: BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline... | |||||||||||||||||||||||
Medical condition: Prevention of breast cancer in women with a BRCA1 germline mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: AT (Ongoing) ES (Ongoing) DE (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005017-23 | Sponsor Protocol Number: FM-14-B02 | Start Date*: 2016-01-26 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Fondazione Michelangelo - Avanzamento dello studio e cura dei tumori | ||||||||||||||||||||||||||||||||||||||
Full Title: Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative, Early High-Risk and Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin | ||||||||||||||||||||||||||||||||||||||
Medical condition: Women with a diagnosis of invasive unilateral, early high-risk and locally advanced or inflammatory, triple negative (HER2-negative and ER-negative and PgRnegative) breast cancer of high proliferat... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) ES (Ongoing) IE (Ongoing) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005639-65 | Sponsor Protocol Number: GEICAM/2017-01_IBCSG62-20_BIG18-04 | Start Date*: 2021-05-25 | ||||||||||||||||
Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama) | ||||||||||||||||||
Full Title: A randomized phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer. “ALPHABET ... | ||||||||||||||||||
Medical condition: PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab and trastuzumab emtansine (T-DM1) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) AT (Completed) FR (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002061-12 | Sponsor Protocol Number: SBG2004-1/ABCSG25/GBG53 | Start Date*: 2007-08-17 | |||||||||||
Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group) | |||||||||||||
Full Title: PANTHER (The SBG 2004-1/ABCSG 25/GBG53 Protocol) - a randomised phase III study: Comparing two weekly and tailored epirubicin + cyclophosphamide followed by two weekly tailored docetaxel (dtEC->dtT... | |||||||||||||
Medical condition: lymph node positive breast cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) FI (Prematurely Ended) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000981-31 | Sponsor Protocol Number: FM-17-B01 | Start Date*: 2019-03-11 | |||||||||||
Sponsor Name:Michelangelo Foundation | |||||||||||||
Full Title: Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer. | |||||||||||||
Medical condition: Women with a diagnosis of non-metastatic high-risk invasive unilateral, HER2-positive breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) BE (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003553-19 | Sponsor Protocol Number: IBCSG59-19/BIG18-02 | Start Date*: 2019-06-25 | ||||||||||||||||
Sponsor Name:International Breat Cancer Study Group (IBCSG) | ||||||||||||||||||
Full Title: A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2... | ||||||||||||||||||
Medical condition: patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) AT (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002018-37 | Sponsor Protocol Number: BO27938 | Start Date*: 2013-04-09 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A RANDOMIZED, MULTICENTER, OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BRE... | ||||||||||||||||||
Medical condition: HER2-positive primary breast cancer. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Ongoing) SE (Ongoing) AT (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) IE (Ongoing) ES (Ongoing) GR (Ongoing) FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001006-28 | Sponsor Protocol Number: 20170770 | Start Date*: 2019-09-13 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of No... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GR (Ongoing) PL (Ongoing) PT (Trial now transitioned) AT (Completed) HU (Ongoing) ES (Ongoing) RO (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002491-39 | Sponsor Protocol Number: SGNTUC-028 | Start Date*: 2022-02-11 | |||||||||||||||||||||
Sponsor Name:Seagen Inc. | |||||||||||||||||||||||
Full Title: A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05) | |||||||||||||||||||||||
Medical condition: Unresectable locally-advanced or metastatic HER2+ breast cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Ongoing) PT (Ongoing) ES (Ongoing) IT (Ongoing) AT (Ongoing) GR (Ongoing) CZ (Ongoing) FI (Ongoing) NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001502-18 | Sponsor Protocol Number: I3YMCJPBM | Start Date*: 2014-11-24 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women ... | |||||||||||||
Medical condition: Hormone Receptor Positive, HER2 negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in This Disease Setting | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) DE (Completed) ES (Ongoing) IT (Ongoing) SK (Completed) BE (Ongoing) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001040-62 | Sponsor Protocol Number: GBG78/BIG1-13 | Start Date*: 2013-11-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse r... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: About one-third of patient with hormone-receptor positive, HER2 negative breast cancer and residual disease after standard of care - including adequate surgery - have a substantial risk of relapse ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) AT (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-005017-39 | Sponsor Protocol Number: SGNTUC-016 | Start Date*: 2021-01-08 | ||||||||||||||||
Sponsor Name:Seagen Inc. | ||||||||||||||||||
Full Title: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast canc... | ||||||||||||||||||
Medical condition: Unresectable locally-advanced or metastatic HER2+ breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) DK (Ongoing) FR (Ongoing) AT (Completed) BE (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) SE (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004035-24 | Sponsor Protocol Number: I3Y-MC-JPCW | Start Date*: 2021-04-26 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company | ||||||||||||||||||
Full Title: eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Brea... | ||||||||||||||||||
Medical condition: High-Risk, Node-Positive, HR+, HER2+ Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) BE (Ongoing) DE (Temporarily Halted) FI (Temporarily Halted) AT (Completed) HU (Completed) GR (Completed) IT (Ongoing) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003839-30 | Sponsor Protocol Number: D081CC00006 | Start Date*: 2014-06-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germl... | |||||||||||||
Medical condition: Adjuvant breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) HU (Trial now transitioned) IT (Ongoing) BE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) AT (Ongoing) IS (Ongoing) PL (Ongoing) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000380-13 | Sponsor Protocol Number: CP-MGAH22-04 | Start Date*: 2015-09-02 | |||||||||||||||||||||
Sponsor Name:MacroGenics, Inc. | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 The... | |||||||||||||||||||||||
Medical condition: Metastatic or Locally Advanced HER2-positive Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) PT (Completed) CZ (Completed) AT (Completed) FI (Completed) ES (Completed) DK (Completed) FR (Ongoing) PL (Completed) IT (Ongoing) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.